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ABSTRACT 
Radiofrequency ablation (RFA) is a well-established local therapy for hepatic malignancies. It is rapidly emerging 
as an effective treatment modality for small lesions elsewhere in the body, in particular, the kidney and the lung. It is a 
relatively safe and minimally invasive treatment for small lung malignancies, both primary and secondary. In particular, 
it is the preferred form of treatment for non-surgical candidates. 
This paper describes the technique employed for radiofrequency ablation of lung tumours, as well as the protocol 
established, at the Mount Elizabeth Hospital, Singapore. © 2006 Biomedical Imaging and Intervention Journal. All 
rights reserved. 
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TECHNIQUE 
Mode of imaging 
All cases are performed under computed 
tomography (CT) fluoroscopic guidance.  
RF system used 
The Valley Lab Cool-tip radio frequency (RF) 
system (Valley Lab, Boulder, CO), with the 17-gauge 
single prong electrode, connected to a 200 W 
radiofrequency generator was used in all cases. The 
length of the exposed tip of the electrode chosen is 1 to 3 
cm depending on the size of the lesion. In general, the 
length of the exposed tip should be greater than the 
diameter of the lesion. For lesions larger than 3 cm in 
diameter, multiple cycles of ablation are performed with 
re-positioning of the electrode between each cycle, to 
achieve overlapping areas of ablation larger than the 
lesion itself. The Cool-tip cluster electrode system was 
not used in any of these cases. Each cycle of ablation is 
12 minutes, as per the standard protocol determined by 
the Valley Lab system for RF ablation under impedance 
control. Track ablation is performed at the end of the 
ablation cycle by switching off the cooling system after 
11 minutes of ablation. The electrode is withdrawn when 
the temperature increases beyond 70ºC. 
The other RF system available in our department is 
the LeVeen needle (Boston Scientific, Watertown, MA). 
This system was not used in any of our lung lesions. It 
was felt that the larger gauge needle and as well as its co-
access or co-axial system subjected the patients to a 
higher risk of pneumothorax. Track ablation is not as 
easily achieved as in the Valley Lab system. The track is 
sequentially ablated at a power of 10 W and withdrawn 
following roll-off.  
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Furthermore, from a purely subjective point of view, 
this author finds the Cool-tip electrode a much easier 
electrode to place into a lesion accurately. It is a slimmer 
and a more flexible electrode. The technique of placing 
the electrode is to skewer the lesion so that the tip of the 
electrode is just distal to the far margin of the lesion. The 
stiffer and larger gauge co-access needle of the LeVeen 
system is more difficult to target lesions with, especially 
lesions with locations that require angling the needle 
superior or inferior to the skin entry point. The system 
also requires that the tip of the needle is a short distance 
away from the far margin of the lesion so that the tines of 
the LeVeen needle, when extended, achieve optimal 
coverage of the lesion. This takes some practice and 
experience and it may involve greater CT-fluoroscopy 
time. Furthermore, it is this author’s opinion that co-
access or co-axial systems in the lung run a higher risk of 
pneumothorax. 
Pre-procedural evaluation 
The CT images are reviewed prior to ablation 
(Figures 1 and 2). The CT images should be recent; no 
more than four weeks prior to the procedure. The number, 
size, and location of the lesions are evaluated. Lesions 
close to vital structures need to be studied carefully as 
these may potentially be damaged by the heat generated 
during RFA. These include the heart, the main 
pulmonary vessels, the trachea, and the main bronchi. In 
general, the major vessels as well as the heart are 
protected from the heat as a result of the blood flow 
resulting in a heat sink effect [10]. Nevertheless, care is 
always taken to ensure that the electrode does not cross 
or abut a major vessel or the heart directly. Arbitrarily, 
the electrode is placed at a minimum of approximately 1 
cm from these structures. Although the heat sink effect 
protects these structures from heat damage, it also 
implies that the portion of the lesion abutting these 
structures may also be protected form heat damage, 
resulting in sub-total ablation. In such cases, alcohol 
ablation of the portion of the tumour abutting the major 
vessels may be considered if RFA alone does not achieve 
complete ablation. 
The clinical history of the patient is also reviewed. 
Care is taken to evaluate co-morbid conditions, 
especially other lung diseases, such as, chronic 
obstructive airway disease, bronchiectasis, and asthma. 
These cases have a higher risk as they will not tolerate 
complications of RFA of the lung, such as, 
pneumothorax and pulmonary haemorrhage. The 
theoretical risks of performing RFA on patients with 
pacemakers seem to be unfounded [10], and the 
procedure has been performed in these patients without 
significant complications. Nevertheless, a cardiologist, in 
particular, an electro-physiologist if available, should 
evaluate all patients with pacemakers. If the patient does 
not require the pacemaker constantly, it may be 
temporarily deactivated at the time of ablation, with 
external pacing on standby. If the patient is entirely 
dependent on the pacemaker and any disruption of its 
function cannot be tolerated, it may be prudent to explore 
other means of local ablative therapy, if available. These 
include laser ablation or microwave ablation, which do 
not employ RF energy.  
The coagulation profile of the patient should always 
be assessed prior to the procedure. 
Contraindications to RFA of lung lesions: 
1.  Coagulopathy 
2.  Extensive lung involvement with life 
expectancy of less than six months 
3.  Invasion of pericardium and mediastinum  
The procedure 
The procedure is performed in the CT fluoroscopy 
room. A pre-RF, unenhanced CT of the thorax is 
performed. The site of the lesion and the entry point are 
chosen. The patient may be turned and re-positioned 
accordingly, e.g., in the prone or oblique position. The 
 
Figure 1  PET/CT image of single lung metastasis for RFA. This 
is a typical lesion and ideal for RFA. 
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shortest possible path to the lesion, avoiding major 
structures and fissures, is usually selected.  
A pleural drainage set is placed in the procedure 
room for use in the case of significant pneumothorax 
requiring immediate chest tube insertion. Usually, a 
simple 6Fr multi-purpose pigtail drainage catheter is all 
that is necessary.  
As in all cases of radiofrequency ablation in our 
department, lung ablations are performed under heavy 
conscious sedation with the aid of an anaesthetist. 
Midazolam, fentanyl, and propofol are titrated during the 
procedure. The patient is placed on intra-nasal oxygen, 
and the vital signs are monitored. No intubation or 
general anaesthetic is required [8]. 
The 17-gauge RF electrode is inserted into the lesion 
under CT fluoroscopic guidance, under strict aseptic 
conditions.  
After the tip of the electrode is successfully placed 
within the lesion (Figure 3), the portion of the electrode 
outside the patient’s body is supported by hand 
throughout the ablation cycle. This is necessary because 
the lung parenchyma is not as firm as the liver 
parenchyma. The weight of the electrode may cause it to 
change position, if left unsupported. Furthermore, 
respiratory movement, progressive atelectasis, and 
change in consistency of the lung parenchyma adjacent 
to the lesion during the ablation may result in a change in 
position of the electrode relative to the lesion. Therefore, 
intermittent CT fluoroscopy is performed during the 
ablation cycle, and the electrode position is readjusted 
appropriately. Arbitrarily, the lesion is imaged every 
three minutes during ablation. 
The water-cooling system is switched off towards 
the end of the cycle, usually after 11 minutes of ablation, 
and the electrode is allowed to heat up. The electrode is 
withdrawn, after the temperature exceeds about 70ºC, to 
coagulate the track. The rationale behind track 
coagulation is to reduce the risk of tumour track seeding 
[9] and to reduce the risk of pneumothorax. 
If the lesion is larger than 3 cm in diameter, the 
water-cooling system is left on for the full 12 minutes. 
The electrode is partially withdrawn at the end of the 
cycle and re-positioned for further ablation. The track is 
not coagulated at this point in time. Re-positioning and 
repeat ablation is performed up to three to four times, 
depending on the size of the lesion. If the lesion requires 
more than three to four cycles of ablation, the procedure 
will be re-scheduled for further ablation one month later. 
Track ablation is only performed during the final 
complete withdrawal of the electrode.  
At present, there is no means of evaluating the 
adequacy of ablation of a lesion during the procedure. 
The end-point of ablation for small lesions (2 to 3 cm) is 
taken as the arbitrary 12-minute cut-off point in the 
Valley Lab Cool-tip system. The Cool-tip system set on 
impedance control will alternate between “on” (active) 
and “off” (inactive) modes depending on the impedance 
of the lesion being ablated. Long periods of inactivity 
(30 to 40 s) by the machine followed by short periods of 
activity (5 to 7 s) with impedance levels of greater than 
100 ohms, indicate that the target volume of tumour has 
been ablated [7]. 
At our centre, the only other RFA system available 
is the LeVeen needle by the Boston Scientific 
Corporation. The end-point of ablation using this system 
is the roll-off when impedance increases rapidly 
following tumour cell death. Till date, however, we have 
not used the LeVeen system for RFA of lung lesions.  
It has been suggested that an indication of complete 
tumour ablation is the presence of a good surrounding 
rim of ground glass opacification around the tumour 
(Figure 4). This is a useful sign to look out for when 
ablating lesions larger than 3 cm, which require multiple 
Figure 3  RF electrode inserted into lesion under CT fluoroscopic 
guidance. Note that the tip of the electrode has gone 
beyond the far margin of the tumour nodule to ensure 
that a good rim of normal lung tissue is also ablated. 
 
 
Figure 4  RFA in progress. Surrounding area of ground glass 
opacification is typical during ablation. There is also 
surrounding focal parenchymal haemorrhage, which is 
sometimes seen during RFA. PYT Goh. Biomed Imaging Interv J 2006; 2(3):e39   4 
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ablations and re-positioning of the electrode to achieve 
overlapping zones of ablation [10]. 
If a pneumothorax is sustained during the insertion 
of the electrode, prior to the actual placement of the 
electrode within the lesion, aspiration may be required. 
This is because the presence of a pneumothorax 
sometimes makes accurate placement of the electrode 
within the lesion difficult. A 6 Fr multiple side-hole 
drainage catheter is usually used. After complete 
aspiration of the pneumothorax, the catheter is left in-situ 
and closed off. If the pneumothorax, however, does not 
interfere with the placement of the electrode and if the 
patient is not clinically compromised, no aspiration is 
necessary. 
An arbitrary maximum of 3 to 4 cycles of ablation 
are performed during a single session of RF ablation. 
This is irrespective of the number of lesions. If more 
cycles of ablation are required or if there are multiple 
lesions, further RFA is performed at a later date, usually 
at one-month intervals.  
RFA for bilateral lung lesions during a single 
session is a relative contraindication. In such patients, it 
is better to perform RF for one side first and to schedule 
the lesions on the contra lateral side to be ablated, a 
month later. Depending on the clinical status of the 
patient and in the absence of complications during the 
ablation on one side, however, ablation of the contra 
lateral lesions may be performed during the same session.  
Post-procedure 
Follow-up serial chest radiographs are performed 
after the procedure, as per standard post-lung biopsy 
protocol, to check for a pneumothorax or to track an 
existing one. Not all cases with pneumothorax require 
chest tube insertion. This is only inserted if the patient is 
symptomatic or if the pneumothorax is large. 
The use of prophylactic antibiotics is debatable. At 
our centre, a single dose of peri-procedural broad-
spectrum antibiotics is usually given.  
Post-procedural analgesia is prescribed only if the 
patients require this. For subpleural lesions, there may be 
pain following the ablation and analgesia may be 
mandatory. Some patients with sub pleural lesions may 
develop a pleural effusion. This is drained 
percutaneuosly only if the patient is symptomatic. 
Follow-up CT of the thorax (Figure 5) with 
intravenous contrast enhancement is performed at one 
month, three months, and six months post-procedure. 
After that, follow-up is at six-month intervals for two 
years and, then, yearly. If the ablation scar shows any 
evidence of increase in size or enhancement, repeat 
ablation may be performed. A review article by Rose et 
al [10] on radiofrequency ablation of lung cancer 
suggests that if there is an increase of at least 10 HU 
between the non-contrast scan and the contrast-enhanced 
scan, this is suggestive of residual viable tumour. Repeat 
ablation is then advised. 
PET/CT scans are far more sensitive than contrast 
enhanced CT scans in detecting recurrent or residual 
viable tumour. Not all patients, however, can afford to be 
followed up with PET/CT. Where possible, a PET/CT is 
recommended at one month post-RFA and at one year, 
with contrast enhanced CT scans in between, at the 
intervals suggested above. 
Tumour markers should be monitored if these were 
elevated, prior to RFA. 
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Figure 5  CT scan performed one-month post-RFA. This is a 
typical appearance of an oval area of coagulation 
necrosis scarring following RFA. Note that the area of 
scarring is larger than the original lesion, indicating a 
positive outcome. 